Histone Deacetylase Inhibitors: The Epigenetic Therapeutics That Repress Hypoxia-Inducible Factors

Histone deacetylase inhibitors (HDACIs) have been actively explored as a new generation of chemotherapeutics for cancers, generally known as epigenetic therapeutics. Recent findings indicate that several types of HDACIs repress angiogenesis, a process essential for tumor metabolism and progression....

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shuyang, Sang, Nianli
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997513/
https://www.ncbi.nlm.nih.gov/pubmed/21151670
http://dx.doi.org/10.1155/2011/197946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997513/
https://www.ncbi.nlm.nih.gov/pubmed/21151670
http://dx.doi.org/10.1155/2011/197946

Ejemplares similares